indoximod + doxorubicin (Nammi Therapeutics)

N/A

Report date: 2025/06/11 11:11:24

Base Information

Drug Nameindoximod + doxorubicin (Nammi Therapeutics)
Drug Alias NameNamm-1doxorubicin + IDO checkpoint inhibitor (Nammi Therapeutics)Nammi-1 immunotherapy (Nammi Therapeutics)dual phospholipid-conjugated prodrug + doxorubicin (Nammi Therapeutics)NTI-101 +[6] 
ClassificationBiologics
Mechanisms of ActionTopoisomerase II inhibitorsT lymphocytes stimulantsImmunostimulants +[4] 
TargetsTopoisomerase IIIndoleamine 2,3-dioxygenase
Therapy Area/IndicationsOvarian NeoplasmsBreast NeoplasmsSarcoma, Kaposi
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California, Los Angeles
China Registration ClassN/A

Develop Information

Active CompaniesNammi Therapeutics Inc
Inactive CompaniesUniversity Of California, Los Angeles
Active IndicationsOvarian NeoplasmsBreast NeoplasmsSarcoma, Kaposi
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A